Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast


Werbung

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes on Wednesday, November 1, 2023.

The Company will hold a conference call at 8:30 a.m. ET on Thursday, November 2, which will be open to the public. During the conference call, the company will review its financial results and provide business updates.

Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.

Werbung

A replay will be available following the conference call, accessible under Events.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter.

Werbung

Aktuelle Sangamo Therapeutics Aktie News

Werbung

Sangamo Therapeutics Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sangamo Therapeutics nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
26.08.19 Sangamo Therapeutics Buy H.C. Wainwright & Co.
01.11.16 Sangamo BioSciences Neutral Wedbush Morgan Securities Inc.
24.04.15 Sangamo BioSciences Outperform BMO Capital Markets
19.10.09 Sangamo BioSciences sell Brean Murray, Carret & Co., LLC
08.10.09 Sangamo BioSciences neues Kursziel Leerink Swann LLC

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.